Unlock stock picks and a broker-level newsfeed that powers Wall Street.
KOSDAQ - Delayed Quote KRW

PharmaResearch Co., Ltd. (214450.KQ)

Compare
335,500.00
-4,000.00
(-1.18%)
At close: April 4 at 3:30:19 PM GMT+9
Loading Chart for 214450.KQ
  • Previous Close 339,500.00
  • Open 335,000.00
  • Bid 331,500.00 x --
  • Ask 332,000.00 x --
  • Day's Range 328,500.00 - 346,500.00
  • 52 Week Range 107,000.00 - 356,500.00
  • Volume 82,647
  • Avg. Volume 104,366
  • Market Cap (intraday) 3.47T
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield 1,100.00 (0.33%)
  • Ex-Dividend Date Dec 27, 2024
  • 1y Target Est 321,444.44

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

pharmaresearch.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 214450.KQ

View More

Performance Overview: 214450.KQ

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

214450.KQ
27.81%
KOSPI Composite Index (^KS11)
2.75%

1-Year Return

214450.KQ
205.28%
KOSPI Composite Index (^KS11)
10.09%

3-Year Return

214450.KQ
264.46%
KOSPI Composite Index (^KS11)
10.61%

5-Year Return

214450.KQ
776.43%
KOSPI Composite Index (^KS11)
42.89%

Compare To: 214450.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 214450.KQ

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    3.47T

  • Enterprise Value

    3.05T

  • Trailing P/E

    37.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.86

  • Price/Book (mrq)

    6.43

  • Enterprise Value/Revenue

    8.70

  • Enterprise Value/EBITDA

    22.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.29%

  • Return on Assets (ttm)

    11.33%

  • Return on Equity (ttm)

    17.23%

  • Revenue (ttm)

    350.12B

  • Net Income Avi to Common (ttm)

    92.04B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    437.35B

  • Total Debt/Equity (mrq)

    36.62%

  • Levered Free Cash Flow (ttm)

    67.22B

Research Analysis: 214450.KQ

View More

Company Insights: 214450.KQ

Research Reports: 214450.KQ

View More

People Also Watch